Dr. Reddy's Laboratories Limited Stock price

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
6,155 INR +1.78% Intraday chart for Dr. Reddy's Laboratories Limited +0.42% +6.16%
Sales 2024 * 278B 3.34B Sales 2025 * 298B 3.57B Capitalization 1,007B 12.07B
Net income 2024 * 54.46B 653M Net income 2025 * 56.36B 676M EV / Sales 2024 * 3.36 x
Net cash position 2024 * 72.87B 874M Net cash position 2025 * 112B 1.35B EV / Sales 2025 * 3 x
P/E ratio 2024 *
18.5 x
P/E ratio 2025 *
17.8 x
Employees 25,863
Yield 2024 *
0.67%
Yield 2025 *
0.69%
Free-Float 91.38%
More Fundamentals * Assessed data
Dynamic Chart
Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Dr. Reddy's Labs Secures Marketing Rights to Treatment for Hypovolemic Shock in India, Nepal MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading MT
Dr. Reddy's Board to Consider Dividend for Fiscal 2024 MT
Pharmazz Inc. and Dr. Reddy's Laboratories Limited Enter into A Licensing Agreement to Market Centhaquine as A Resuscitative Agent for Hypovolemic Shock in India CI
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
Dr. Reddy?s Laboratories Ltd. Launches Versavo® (Bevacizumab) in United Kingdom CI
Losses Led by IT Drag Indian Equities on Tuesday MT
Dr. Reddy's Laboratories Launches Versavo Drug in UK MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading MT
Asian Equities Traded in the US as American Depositary Receipts End Week Lower in Friday Trading MT
Dr. Reddy's Laboratories Limited Approves Incorporation of A Wholly-Owned Subsidiary of the Company CI
More news

Latest transcript on Dr. Reddy's Laboratories Limited

1 day+1.78%
1 week+0.42%
Current month-4.13%
1 month-4.23%
3 months+5.25%
6 months+13.45%
Current year+6.16%
More quotes
1 week
6 035.50
Extreme 6035.5
6 299.70
1 month
6 022.00
Extreme 6022
6 472.00
Current year
5 523.45
Extreme 5523.45
6 505.50
1 year
4 383.40
Extreme 4383.4
6 505.50
3 years
3 655.00
Extreme 3655
6 505.50
5 years
2 352.00
Extreme 2352
6 505.50
10 years
1 888.00
Extreme 1888
6 505.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 18-04-01
Director of Finance/CFO - 20-11-01
Chairman 56 93-01-17
Members of the board TitleAgeSince
Chairman 63 86-04-07
Chairman 56 93-01-17
Director/Board Member 73 07-06-04
More insiders
Date Price Change Volume
24-03-28 6,155 +1.78% 13 702
24-03-27 6,048 -1.30% 3,529
24-03-26 6,127 -1.20% 263,678
24-03-22 6,202 +1.18% 7,442
24-03-21 6,129 +0.45% 2,323

Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT

More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
6,048 INR
Average target price
5,978 INR
Spread / Average Target
-1.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Dr. Reddy's Laboratories Limited - Bombay S.E.